智核生物 is a clinical-stage biopharmaceutical company focused on discovering and developing innovative biologic products for molecular nuclear oncology, covering both diagnostics and therapies. The company aims to develop novel drug products to provide improved treatment options for cancer patients. The article does not disclose specific programs, revenues, or operating metrics. Recently the company completed a C+ financing round of nearly RMB 100 million. The round was led by 元禾控股 with follow-on investment from 裕智资本, 见素资本, and 苏州领军创投; existing investor 锐合资本 continued to support the company. 行远致同 served as the chief financial advisor to the transaction.

Total raised

$14M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2024